The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Identification of small molecule inhibitors of pyruvate kinase M2
Open accessAbstract
A common feature of tumors arising from diverse tissue types is a reliance on aerobic glycolysis for glucose metabolism. This metabolic difference between cancer cells and normal cells could be exploited for therapeutic benefit in patients. Cancer cells universally express the M2 isoform of the glycolytic enzyme pyruvate kinase (PKM2), and previous work has demonstrated that PKM2 expression is necessary for aerobic glycolysis and cell proliferation in vivo. Because most normal tissues express an isoform of pyruvate kinase other than PKM2, selective targeting of PKM2 provides an opportunity to target cell metabolism for cancer therapy. PKM2 has an identical catalytic site as the related M1 splice variant (PKM1). However, isoform selective inhibition is possible as PKM2 contains a unique region for allosteric regulation. We have screened a library of greater than 100,000 small molecules to identify such inhibitors. The inhibitors identified for PKM2 fell primarily into three distinct structural classes. The most potent PKM2 inhibitor resulted in decreased glycolysis and increased cell death following loss of growth factor signaling. At least part of this effect was due to on-target PKM2 inhibition as less cell death was observed in cells engineered to express PKM1. These data suggest that isoform selective inhibition of PKM2 with small molecules is feasible and support the hypothesis that inhibition of glucose metabolism in cancer cells is a viable strategy to treat human malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Self-citationCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 1×
“This phenomenon, known as the Warburg effect, is characterized by increased glycolysis with lactate production and decreased oxidative phosphorylation [3,4].”
BackgroundTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Self-citationTumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816
Self-citationMetabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Zahra, K., Dey, T., Ashish, Mishra, S. P., & Pandey, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00159 · Cited by 501
Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth
Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492
Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass
Spinelli, J. B., Yoon, H., Ringel, A. E., Jeanfavre, S., Clish, C. B., & Haigis, M. C. (2017) · Science · doi:10.1126/science.aam9305 · Cited by 468
Emerging roles of PKM2 in cell metabolism and cancer progression
Luo, W., & Semenza, G. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.010 · Cited by 376
Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis
Wang, Y.-H., Israelsen, W. J., Lee, D., Yu, V. W. C., Jeanson, N. T., Clish, C. B., Cantley, L. C., Vander Heiden, M. G., & Scadden, D. T. (2014) · Cell · doi:10.1016/j.cell.2014.07.048 · Cited by 348
Self-citationPKM2 contributes to cancer metabolism
Wong, N., Ojo, D., Yan, J., & Tang, D. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.031 · Cited by 348
PKM2 and cancer: The function of PKM2 beyond glycolysis
DONG, G., MAO, Q., XIA, W., XU, Y., WANG, J., XU, L., & JIANG, F. (2016) · Oncology Letters · doi:10.3892/ol.2016.4168 · Cited by 325
Therapeutic targets in cancer cell metabolism and autophagy
Cheong, H., Lu, C., Lindsten, T., & Thompson, C. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2285 · Cited by 315
Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer
Chaneton, B., & Gottlieb, E. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.04.003 · Cited by 294
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 280
Techniques to Monitor Glycolysis
TeSlaa, T., & Teitell, M. A. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-416618-9.00005-4 · Cited by 273
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & San Martin, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 259
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
Fan, T., Sun, G., Sun, X., Zhao, L., Zhong, R., & Peng, Y. (2019) · Cancers · doi:10.3390/cancers11030317 · Cited by 171
Coordinating Bacterial Cell Division with Nutrient Availability: a Role for Glycolysis
Monahan, L. G., Hajduk, I. V., Blaber, S. P., Charles, I. G., & Harry, E. J. (2014) · mBio · doi:10.1128/mbio.00935-14 · Cited by 123
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
Wang, J., Zhou, S., Cheng, Y., Cheng, L., Qin, Y., Zhang, Z., Bi, A., Xiang, H., He, X., Tian, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01563 · Cited by 18
Metadata
- Authors
- Vander Heiden, M. G., Christofk, H. R., Schuman, E., Subtelny, A. O., Sharfi, H., Harlow, E. E., Xian, J., & Cantley, L. C.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 79
- Issue
- 8
- Pages
- 1118-1124
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2082410084
- Cited by
- 237
- References
- 6
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.